Literature DB >> 17390051

Altered Calreticulin expression in human colon cancer: maintenance of Calreticulin expression is associated with mucinous differentiation.

C Toquet1, A Jarry, C Bou-Hanna, K Bach, M G Denis, J F Mosnier, C L Laboisse.   

Abstract

Calreticulin is an endoplasmic reticulum luminal calcium-binding chaperone involved in various cellular functions and is a ligand for the scavenger receptor CD91. Recent studies, based on proteomic approaches on whole tissue samples containing both neoplastic and non-neoplastic cells, have shown alterations of Calreticulin expression in colon carcinomas, albeit with divergent results. The aims of this study were: 1) to assess the expression of Calreticulin and its receptor CD91 in 58 human colon adenocarcinomas, compared with paired normal mucosa, using a semi-quantitative immunohistochemical analysis, and 2) to examine associations between the tumour phenotypic features, and Calreticulin and/or CD91 expressions. Calreticulin expression was down-regulated in 51.7% human colon adenocarcinomas. Accordingly, quantitative immunoblot analysis showed that Calreticulin expression was significantly lower in human colonic cancer cell lines than in preparations of isolated human normal colonic epithelial cells. CD91 was co-expressed with Calreticulin in both normal colonic epithelial cells and pericryptic myofibroblasts. Calreticulin and CD91, that characterize the 'amateur phagocyte' function of epithelial cells, were both down-regulated in 48% of adenocarcinomas. Finally, Calreticulin expression was significantly associated with the mucinous differentiation of the tumour. Collectively, these results show that Calreticulin is likely to play a pivotal role in the differentiation of human colonic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390051     DOI: 10.3892/or.17.5.1101

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer.

Authors:  Rui-Qing Peng; Ying-Bo Chen; Ya Ding; Rong Zhang; Xing Zhang; Xing-Juan Yu; Zhi-Wei Zhou; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics.

Authors:  Shu-Qin Jia; Zhao-Jian Niu; Lian-Hai Zhang; Xi-Yao Zhong; Tao Shi; Hong Du; Gui-Guo Zhang; Ying Hu; Xiu-Lan Su; Jia-Fu Ji
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-01       Impact factor: 4.553

3.  LRP1 expression in colon cancer predicts clinical outcome.

Authors:  Camille Boulagnon-Rombi; Christophe Schneider; Chloé Leandri; Albin Jeanne; Virginie Grybek; Aude Marchal Bressenot; Coralie Barbe; Benjamin Marquet; Saviz Nasri; Christelle Coquelet; Caroline Fichel; Nicole Bouland; Arnaud Bonnomet; Reza Kianmanesh; Anne-Sophie Lebre; Olivier Bouché; Marie-Danièle Diebold; Georges Bellon; Stéphane Dedieu
Journal:  Oncotarget       Date:  2018-01-13

4.  High expression of calreticulin indicates poor prognosis and modulates cell migration and invasion via activating Stat3 in nasopharyngeal carcinoma.

Authors:  Yaqian Han; Qianjin Liao; Heran Wang; Shan Rao; Pin Yi; Lu Tang; Yutong Tian; Linda Oyang; Hui Wang; Yingrui Shi; Yujuan Zhou
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

Review 5.  Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Authors:  Karthik Dhatchinamoorthy; Jeff D Colbert; Kenneth L Rock
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

6.  Calreticulin increases growth and progression of natural killer/T-cell lymphoma.

Authors:  Yan Zheng; Chuntuan Li; Pengliang Xin; Qunyi Peng; Weiyu Zhang; Shengquan Liu; Xiongpeng Zhu
Journal:  Aging (Albany NY)       Date:  2020-11-18       Impact factor: 5.682

7.  Changes in the in vitro activity of platinum drugs when administered in two aliquots.

Authors:  Zaynab Al-Eisawi; Philip Beale; Charles Chan; Jun Qing Yu; Nicholas Proschogo; Mark Molloy; Fazlul Huq
Journal:  BMC Cancer       Date:  2016-08-26       Impact factor: 4.430

8.  Calreticulin and integrin alpha dissociation induces anti-inflammatory programming in animal models of inflammatory bowel disease.

Authors:  Masayoshi Ohkuro; Jun-Dal Kim; Yoshikazu Kuboi; Yuki Hayashi; Hayase Mizukami; Hiroko Kobayashi-Kuramochi; Kenzo Muramoto; Manabu Shirato; Fumiko Michikawa-Tanaka; Jun Moriya; Teruya Kozaki; Kazuma Takase; Kenichi Chiba; Kishan Lal Agarwala; Takayuki Kimura; Makoto Kotake; Tetsuya Kawahara; Naoki Yoneda; Shinsuke Hirota; Hiroshi Azuma; Nobuko Ozasa-Komura; Yoshiaki Ohashi; Masafumi Muratani; Keiji Kimura; Ieharu Hishinuma; Akiyoshi Fukamizu
Journal:  Nat Commun       Date:  2018-05-17       Impact factor: 14.919

9.  Calreticulin promotes EMT in pancreatic cancer via mediating Ca2+ dependent acute and chronic endoplasmic reticulum stress.

Authors:  Weiwei Sheng; Guosen Wang; Jingtong Tang; Xiaoyang Shi; Rongxian Cao; Jian Sun; Yi Heng Lin; Chao Jia; Chuanping Chen; Jianping Zhou; Ming Dong
Journal:  J Exp Clin Cancer Res       Date:  2020-10-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.